Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors

RICHMOND, Calif., June 29, 2017

"Roger and Joe bring years of leadership experience in drug development, manufacturing, commercialization, and business development, and we are delighted to welcome them both to Sangamo's Board of Directors," said Dr. Sandy Macrae, Chief Executive Officer of Sangamo. "Sangamo is at an important inflection point, and their deep knowledge and expertise will be highly valuable as we accelerate the clinical translation of our ground-breaking science into genomic medicines for patients."

Dr. Jeffs currently serves as a Senior Advisor to United Therapeutics Corp., where he worked for 18 years, most recently as President and co-CEO. He has over 25 years of experience in the biopharmaceutical industry in R&D, clinical development, regulatory and medical affairs. While at United Therapeutics, Dr. Jeffs led the clinical development, regulatory approval and commercialization of six rare disease products. Prior to joining United Therapeutics, he held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs currently serves as a member of the board of directors of Axsome Therapeutics and Dova Pharmaceuticals. He received a B.A. in Chemistry from Duke University and his Ph.D. in Pharmacology from the University of North Carolina.

Mr. Zakrzewski has over 25 years of experience in the biopharmaceutical industry with senior leadership experience in R&D, supply chain and manufacturing operations, business development and commercialization. From 2010 through 2013, he was Chairman and CEO of Amarin Pharmaceuticals, where he led the development and commercialization of the company's first product, Vascepa. Mr. Zakrzewski previously served as a Venture Partner with Orbimed Advisors, a venture capital firm, and as Chairman, President and CEO of Xcellerex, a privately held company focused on the commercialization of its proprietary manufacturing technology for biotherapeutics and vaccines. Earlier, he served as COO of Reliant Pharmaceuticals before its acquisition by GlaxoSmithKline in 2007 and held various executive positions at Eli Lilly & Company in the areas of R&D, manufacturing, finance and business development. Mr. Zakrzewski currently serves as a member of the board of directors of various public and private companies, including Acceleron Pharma, Amarin Pharmaceuticals Insulet Corporation and Onxeo SA where he serves as Chairman. Mr. Zakrzewski received a B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University, and an M.B.A. in Finance from Indiana University.

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences. For more information about Sangamo, visit www.sangamo.com.

Forward-Looking Statements
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, the Company's plans for and pace of development and potential commercialization of its product candidates. Actual results may differ materially from these forward-looking statements due to a number of factors, including risks related to the ability of the Company to successfully develop and commercialize any of its product candidates. Additional risks and uncertainties relating to Sangamo and its business can be found under the heading "Risk Factors" in Sangamo's most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, which was filed with the SEC on May 10, 2017. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Sangamo assumes no obligation to update the forward-looking information contained in this press release.